Bixiye
2020 March Bulletins
Taariikhda uu dhaqangalayo Barnaamijka: Mar 02, 2020
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 2441 - 2450 ee natiijooyinka 3167
Bixiye
P18-20 Lab Management Clinical Guideline Updates for Fully Insured Commercial and Medicare Advantage Subscribers – eviCore Healthcare Specialty Utilization Management (UM) Program
Taariikhda uu dhaqangalayo Barnaamijka: Mar 02, 2020
Bixiye
P17-20 Medical Oncology Drug Prior Authorization Updates for Fully Insured Commercial and Medicare Advantage Subscribers – eviCore Healthcare Specialty Utilization Management (UM) Program
Taariikhda uu dhaqangalayo Barnaamijka: Mar 02, 2020
Bixiye
QP23-20 Blue Cross Basic Seminar Now Available On-Demand through the Availity Portal
Taariikhda uu dhaqangalayo Barnaamijka: 26, Feb 2020
Bixiye
2020 March Provider Press
Taariikhda uu dhaqangalayo Barnaamijka: 24, Feb 2020
Bixiye
QP20-20 Medical Drug Update for New to Market Teprotumumab-trbw (Tepezza)
Taariikhda uu dhaqangalayo Barnaamijka: 12, Feb 2020
Bixiye
QP17-20 Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Wakix ®
Taariikhda uu dhaqangalayo Barnaamijka: 12, Feb 2020
Bixiye
QP14R1-20 Update: New Service Type Options for Inpatient Admission Notifications on Availity Portal
Taariikhda uu dhaqangalayo Barnaamijka: 12, Feb 2020
Bixiye
QP21-20 Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Baclofen
Taariikhda uu dhaqangalayo Barnaamijka: 12, Feb 2020
Bixiye
QP18-20 Pharmacy Benefit Exclusion for Calcipotriene-Betamethasone Dipropionate Suspension 0.005-0.064% (authorized generic (AG) of Taclonex suspension)
Taariikhda uu dhaqangalayo Barnaamijka: 12, Feb 2020